Methods of Treating Conditions Associated with the S1P1 Receptor
Patent Information
- Application Number
- JP2023526166
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-09
- Filing Date
- 2021-11-08
- Publication Date
- 2024-11-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
【0009】 皮膚兆候であるアトピー性皮膚炎を有する患者におけるS1Pモジュレーターについての最初の臨床試験が、本明細書において記載される。リンパ球の減少は、エトラシモドのオンターゲット効果である。研究の間、一部の治験担当医は、リンパ球のレベルがCTCAEグレード3の基準を満たしたため、エトラシモドを中止した。このことは試験の課題を示したが、これはまた、エトラシモドでの処置の中断および再開の効果を評価する予想外の機会ももたらした。試験結果の分析は、投与の中断を伴う患者コホートが、中止後に臨床的リバウンド(またはアトピー性皮膚炎の悪化)を、またエトラシモドでの処置の再開後に臨床効果の回復を示したことを明らかにした。さらに、この所見は、当該患者コホートにおける薬力学的所見と一致した。重要なことに、これらの患者の誰も、処置の中断を正当化することになる感染を示さなかった。
Abstract
Claims
1. For use in a method for treating moderate to severe atopic dermatitis in a patient in need thereof. A pharmaceutical composition comprising etrasimod or a pharma- ceutical acceptable salt thereof, The method further comprising: administering said pharmaceutical composition to a patient in need thereof; (a) identifying a threshold absolute lymphocyte count (ALC) in the patient, where the threshold ALC is less than 500 / mm 3 , or between 0.2×10e9 cells / L and 0.5×10e9 cells / L; or (b) monitoring the patient for one or more infections after administration of the pharmaceutical composition; If the ALC level is below a threshold level or if one or more infections are identified, ceasing administration of the pharmaceutical composition for a discontinuation period; and and continuing administration of said pharmaceutical composition for a continuous period after administration has ceased for a discontinuation period. Including, The pharmaceutical composition is administered in an amount equivalent to 1 to 5 mg of etrasimod. Pharmaceutical compositions.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered once a day for a sustained period of time.
3. A pharmaceutical composition described in any one of claims 1 to 2, wherein the pharmaceutical composition is administered in an amount equivalent to 2 mg of etrasimod or an amount equivalent to 3 mg of etrasimod.
4. 4. The pharmaceutical composition of claim 1, wherein the discontinuation period is at least one week or the duration is at least one month.
5. 5. The pharmaceutical composition of claim 1, wherein the patient has been diagnosed with moderate atopic dermatitis and has a vIGA score of 3, or has been diagnosed with severe atopic dermatitis and has a vIGA score of 4.
6. 5. The pharmaceutical composition of claim 1, wherein the patient has atopic dermatitis of 10% or more of the body surface area (BSA).
7. A pharmaceutical composition described in any one of claims 1 to 6, wherein the method comprises the step of (a) identifying a threshold absolute lymphocyte count (ALC) in the patient and further comprises the step of testing circulating blood levels of lymphocytes in the patient.
8. The method of claim 1, further comprising: (b) monitoring the patient for one or more infections after administration of the pharmaceutical composition; 7. The pharmaceutical composition of claim 1, further comprising the step of monitoring the patient for infection after the discontinuation period and continuing the cessation of treatment if infection is identified.
9. The method of claim 1, further comprising: (b) monitoring the patient for one or more infections after administration of the pharmaceutical composition; 9. The pharmaceutical composition of any one of claims 1 to 6 and 8, wherein the one or more infections are selected from a urinary tract infection, an ear infection, the common cold, diphtheria, E. coli, giardiasis, HIV / AIDS, mononucleosis, influenza, Lyme disease, measles, meningitis, mumps, pneumonia, Salmonella infection, a respiratory infection, shingles, herpes, tuberculosis, viral hepatitis, or COVID-19.
